PUBLISHER: DataM Intelligence | PRODUCT CODE: 1279706
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1279706
Global Biobetters Market - 2023-2030
Market Overview
The global biobetters market size reached US$ 45,336.0 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 85,917.0 million by 2030. The global biobetters market is exhibiting at a CAGR of 8.5% during the forecast period (2023-2030).
The market trends of biobetters are PEGylation fusion proteins, EKylation, XTEN technology, Pasylation, and so on. Fusion proteins are created by combining genes that encode separate proteins. The single polypeptide produced displays the functional properties of both originator biomolecules.
Commonly, one partner has a molecular recognition function while the other transfers a certain functionality, such as decreased cytotoxicity, improved half-life, and stability, novel targeting, or a new delivery route.The global biobetters market is driven by factors such as longer product half-life, lower likelihood of aggregation, greater efficacy, purity, and fewer adverse events and the increasing biosimilar competition restraints the biobetters market growth.
Market Dynamics
The Advantage of Lower Adverse Effect of Biobetters
Biobetters are biotechnological advancements that have lower adverse effects, longer product half-life, greater efficacy, and other driving factors, driving the market growth.
A biobetter can be assigned a premium price due to its improved characteristics, but cost savings can be achieved due to reduced dosages. This affects payers' willingness to purchase the product.
Growing Demand for PEGylation, and XTEN Technology
PEGylation is the covalent attachment of polyethylene glycol (PEG) chains to a functional molecule, which is effective in improving pharmacokinetics and reducing toxicity and immunogenicity. It has become the main approach to overcome the limitations of biological drugs, with an increasing number of PEGylated products on the market. PEGylated proteins are characterized by increased size and hydrodynamic volume, reduced immunogenicity, protection against in vivo proteolysis and endocytosis, greater solubility in water, decreased protein aggregation due to steric repulsion, and increased thermal and mechanical stability.
XTEN technology also known as XTENylation is a genetic fusion of an unstructured recombinant polypeptide of 864 amino acids, composed entirely of alanine, glutamate, glycine, proline, serine, and threonine residues. It has been demonstrated to increase the serum half-life and water solubility and stability of proteins, allowing their expression in solution and manufacturing.
Increasing Biosimilar Competition
Increasing biosimilar competition for the biobetters restraining the market growth during the forecast period. Advancements in the development of biosimilars is decreasing the demand for biobetter market.
COVID-19 Impact Analysis
Autoimmune conditions such as rheumatoid arthritis or inflammatory bowel disease are at higher risk of COVID-19 infection, and then new guidance was issued in the UK to ensure that patients receiving intravenous treatment were assessed for possible switching to the same therapy in subcutaneous form.
This switch from hospital-based intravenous infusion therapy to administration via subcutaneous injection is an example of how biobetters, a new generation of innovative therapeutic medicines, could become an important tool to help ensure that patients can gain access to the treatment they need in a timely fashion. During the COVID-19 pandemic, advancements in the biobetters are seen, and some anticipating conditions have also been noticed.
Russia-Ukraine Conflict Analysis
Risk about the war's long-term impact on the scientific community worldwide and the missed opportunities for research in Ukraine's academic, medical, and scientific disciplines during Russia Ukraine war.
Ukraine was testing 251 medicines, devices, and drugs, according to the FDA's clinical trials database. According to the clinical trials database, in 2022, over 1,000 medication clinical trials were underway or planned in Ukraine. The Russia-Ukraine war impacted the biobetters market, resulting in increased demand for medicines, drugs, and medical devices, and in some cases decreased demand for the biobetters market in the region.
Segment Analysis
The global biobetters market is segmented based on Drug Class, By Application, By Route of Administration and By Distribution Channel.
Bispecific Antibodies Biobetters Segment is Expected to Dominate the Biobetters Market
The bispecific antibodies biobetters segment is expected to dominate the biobetters capturing a market share of around 36.1%. The advanced healthcare infrastructure coupled with rapid advancements in technology is expected to play an imperative role in boosting the growth of the biobetters market in the forecast period.
Bispecific antibodies (BsAbs) consist of two binding sites directed at two antigens or two epitopes of the same antigen. The primary application of BsAbs has been to shift cytotoxic immune effector cells for the enhanced killing of tumor cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and other cytotoxic mechanisms carried out by the effector cells.
Geographical Analysis
North America Region Holds the Largest Market Share of Around 39.4% in the Global Biobetters Market
Biobetters are approved through the biologics approval pathway, providing 10-12 years of market exclusivity in the North American region. The United States is the global leader in the Biopharmaceutical market, accounting for one-third of the global market. Over half of the world's R&D and Intellectual Property Rights of most new medicines are held by the United States.
Competitive Landscape
The major global players include: Amgen Inc., Merck KGaA., Mabpharm Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Celltrion Healthcare, Novo Nordisk A/S, Biogen, Aequilibrium Pharma, Pfizer, and others.
Why Purchase the Report?
- To visualize the global biobetters market segmentation based on product, application, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global biobetters market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global biobetters market report would provide approximately 54 tables, 46 figures, and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Drug Class
- 3.2. Snippet by Application
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Lower adverse effects
- 4.1.1.2. Longer Product Half-life
- 4.1.2. Restraints
- 4.1.2.1. Increasing Biosimilar Competition
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturer's Strategic Initiatives
- 6.6. Conclusion
7. By Drug Class
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Bispecific Antibodies Biobetters
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. PEGylation Biobetters
- 7.4. Glyco-engineering Biobetters
- 7.5. Fc Engineering Biobetters
- 7.6. Antibody Fragment Biobetters
- 7.7. Antibody Drug Conjugation (ADC) Biobetters
- 7.8. Fusion Protein Biobetters
- 7.9. Bio Prodrug/Bioprecursor Biobetters
8. By Application
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Cancer*
- 8.2.1. Introduction
- 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Diabetes
- 8.4. Renal Disease
- 8.5. Neurodegenerative Disease
- 8.6. Genetic Disorders
8. By Route of Administration
- 8.5. Introduction
- 8.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.5.2. Market Attractiveness Index, By Route of Administration
- 8.6. Subcutaneous
- 8.6.1. Introduction
- 8.6.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.7. Intravenous
- 8.8. Oral
- 8.9. Inhaled
- 8.10. Intramuscular
9. By Region
- 9.5. Introduction
- 9.5.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.5.2. Market Attractiveness Index, By Region
- 9.6. North America
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.6.7.1. Canada
- 9.6.7.2. Mexico
- 9.7. Europe
- 9.7.1. Introduction
- 9.7.2. Key Region-Specific Dynamics
- 9.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.7.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.7.7.1. Germany
- 9.7.7.2. The U.K.
- 9.7.7.3. France
- 9.7.7.4. Italy
- 9.7.7.5. Spain
- 9.7.7.6. Rest of Europe
- 9.8. South America
- 9.8.1. Introduction
- 9.8.2. Key Region-Specific Dynamics
- 9.8.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.8.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.8.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.8.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.8.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.8.7.1. Brazil
- 9.8.7.2. Argentina
- 9.8.7.3. Rest of South America
- 9.9. Asia-Pacific
- 9.9.1. Introduction
- 9.9.2. Key Region-Specific Dynamics
- 9.9.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.9.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.9.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.9.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.9.7.1. China
- 9.9.7.2. India
- 9.9.7.3. Japan
- 9.9.7.4. Australia
- 9.9.7.5. Rest of Asia-Pacific
- 9.10. Middle East and Africa
- 9.10.1. Introduction
- 9.10.2. Key Region-Specific Dynamics
- 9.10.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 9.10.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10. Competitive Landscape
- 10.5. Competitive Scenario
- 10.6. Market Positioning/Share Analysis
- 10.7. Mergers and Acquisitions Analysis
11. Company Profiles
- 11.5. Amgen Inc*
- 11.5.1. Company Overview
- 11.5.2. Product Portfolio and Description
- 11.5.3. Financial Overview
- 11.5.4. Key Developments
- 11.6. Merck KGaA.
- 11.7. Mabpharm Limited
- 11.8. F. Hoffmann-La Roche Ltd
- 11.9. GlaxoSmithKline plc
- 11.10. CELLTRION INC.
- 11.11. Novo Nordisk A/S
- 11.12. Biogen
- 11.13. Aequilibrium Pharma
- 11.14. Pfizer Inc
LIST NOT EXHAUSTIVE
12. Appendix
- 12.5. About Us and Services
- 12.6. Contact Us
